African Americans Fighting Alzheimer’s in Midlife (AA-FAIM)

非裔美国人中年抗击阿尔茨海默病 (AA-FAIM)

• 批准号: 10589654
• 负责人: CAREY E GLEASON
• 金额: $ 274.46万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-01 至 2027-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10589654
• 关键词: Acceleration; Address; Adult; Affect; African American population; Age; Age of Onset; Alzheimer disease detection; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Alzheimer’s disease biomarker; American; Amyloid; Amyloid beta-Protein; Amyloidosis; Area; Belief; Biological Markers; Black American; Black Populations; Black race; Cerebrovascular Disorders; Cerebrum; Chronic; Clinical; Clinical Research; Cognition; Cognitive; Collection; Data; Data Set; Dementia; Diabetes Mellitus; Disclosure; Disease; Disease model; Disparity; Emotions; Enrollment; Event; Family history of; Functional disorder; Goals; Impaired cognition; Impairment; Individual; International; Investments; Link; Longitudinal cohort; Meta-Analysis; Metabolic Diseases; Methods; Minority Groups; Mission; Modeling; Not Hispanic or Latino; PET positivity; Participant; Pathologic; Pattern; Perception; Plasma; Population; Positron-Emission Tomography; Pre-Clinical Model; Predictive Factor; Psychosocial Factor; ROC Curve; Race; Research; Risk; Role; Sampling; Sleep; Stressful Event; Testing; Time; Trust; United States National Institutes of Health; Visit; Work; abeta accumulation; abeta deposition; age related; archived data; black patient; caucasian American; cohort; falls; fighting; health disparity; improved; middle age; patient engagement; pattern perception; perceived discrimination; pre-clinical; predictive modeling; processing speed; prognostic value; programs; prospective; psychosocial; recruit; retention rate; success; symposium; tau Proteins; theories; vascular risk factor

1 PROJECT SUMMARY 2 The overarching goals of the African Americans Fighting Alzheimer’s in Midlife (AA-FAIM) renewal are to 3 promote timely and valid detection of Alzheimer’s disease (AD) and related dementias (ADRD) in Black 4 populations and to increase inclusion of Black adults in ADRD research. Being racialized as Black in the US is 5 associated with twice the risk of cognitive decline and ADRD relative to non-Hispanic whites. Yet, because Black 6 Americans are substantially under-recruited and under-represented in ADRD research, gaps remain in our 7 understanding of the generalizability of prevailing theories of preclinical AD pathophysiology (e.g. the amyloid 8 hypothesis) to Black patients. To address these gaps, we must obtain essential biomarker data from Black 9 participants and improve inclusion of Black participants, examining recruitment/retention with scientific rigor. In 10 Aim 1, we will explore the relevance of preclinical amyloidosis in predicting cognitive decline in a Black cohort, 11 comparing models considering roles of (a) preclinical AD pathology, (b) vascular risk factors, (c) psychosocial 12 factors, and (d) cognitive markers in predicting cognitive decline in a cohort of 400 Black adults. Aim 2 will 13 examine the association between plasma Aß42/40 and Amyloid PET positivity (PET A+) and test the 14 chronicity/EAOA (estimated age of amyloid onset) model of preclinical AD in Black participants. We will 15 investigate associations between plasma Aß42/40 and concurrent PET A+, and assess whether longer amyloid 16 chronicity and/or earlier EAOA are associated with accelerated cognitive decline. Aim 3 examines factors 17 associated with successful enrollment and retention. We will assess patterns of perceptions and beliefs relative 18 to an emerging model of participant engagement, and explore model constructs’ efficacy in predicting 19 prospective participation decisions. With renewed investment in the AA-FAIM cohort, we will continue 20 contributing to an emerging understanding of preclinical ADRD in a minoritized population. Moreover, we can 21 further leverage our participants’ contributions by partnering with teams seeking access to these unique data.

1 项目概要 2 非裔美国人中年抗击阿尔茨海默病 (AA-FAIM) 更新的总体目标是 3 促进及时有效地检测黑人中的阿尔茨海默病 (AD) 和相关痴呆症 (ADRD) 4 人群并增加黑人成人参与 ADRD 研究。在美国被种族化为黑人是 5 与非西班牙裔白人相比，认知能力下降和 ADRD 风险高出两倍。然而，因为黑 6 美国人在 ADRD 研究中的招募和代表性严重不足，我们的研究中仍然存在差距 7 了解临床前 AD 病理生理学主流理论的普遍性（例如淀粉样蛋白 8 假设）针对黑人患者。为了解决这些差距，我们必须从 Black 获得重要的生物标志物数据 9 名参与者并提高黑人参与者的包容性，以科学严谨的方式检查招募/保留情况。在 10 目标 1，我们将探讨临床前淀粉样变性在预测黑人群体认知能力下降方面的相关性， 11 个比较模型考虑了 (a) 临床前 AD 病理学、(b) 血管危险因素、(c) 社会心理的作用 12 个因素和 (d) 认知标记可预测 400 名黑人成年人的认知能力下降。目标2将 13 检查血浆 Aß42/40 和淀粉样蛋白 PET 阳性 (PET A+) 之间的关联并测试 14 黑人参与者临床前 AD 的慢性/EAOA（淀粉样蛋白发病估计年龄）模型。我们将 15 研究血浆 Aß42/40 与并发 PET A+ 之间的关联，并评估淀粉样蛋白是否更长 16 慢性和/或早期 EAOA 与认知能力加速下降有关。目标 3 检查因素 17 与成功注册和保留相关。我们将评估相对的认知和信念模式 18 一个新兴的参与者参与模型，并探索模型构建在预测方面的功效 19 项预期参与决定。随着对 AA-FAIM 队列的重新投资，我们将继续 20 有助于对少数群体中临床前 ADRD 的新认识。此外，我们还可以 21 通过与寻求访问这些独特数据的团队合作，进一步利用参与者的贡献。